摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氰基-5-甲基苯磺酰氯 | 197960-31-9

中文名称
2-氰基-5-甲基苯磺酰氯
中文别名
——
英文名称
2-cyano-5-methylbenzene-1-sulfonyl chloride
英文别名
2-cyano-5-methyl-benzenesulfonyl chloride;2-cyano-5-methylbenzenesulfonyl chloride;2-Cyan-5-methyl-benzolsulfonylchlorid
2-氰基-5-甲基苯磺酰氯化学式
CAS
197960-31-9
化学式
C8H6ClNO2S
mdl
——
分子量
215.66
InChiKey
ZFQDREVAYVNITB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    71 °C
  • 沸点:
    382.0±35.0 °C(Predicted)
  • 密度:
    1.46±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    66.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R20/21/22,R34
  • 海关编码:
    2926909090

SDS

SDS:f0db6e99b04ed7eb6f33acab1d516c0b
查看
Name: 2-Cyano-5-methylbenzenesulfonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS: 197960-31-9
Section 1 - Chemical Product MSDS Name:2-Cyano-5-methylbenzenesulfonyl chloride 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
197960-31-9 2-Cyano-5-methylbenzenesulfonyl chlori 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 197960-31-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6ClNO2S
Molecular Weight: 215.66

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines, alcohols.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 197960-31-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Cyano-5-methylbenzenesulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.*
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 197960-31-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 197960-31-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 197960-31-9 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氰基-5-甲基苯磺酰氯吡啶1,3-二甲基-2-咪唑啉酮 作用下, 以 1,4-二氧六环二氯甲烷 为溶剂, 反应 32.0h, 生成 1-[6-[4-[(2-fluoro-5-methyl-phenyl)sulfonylamino]phenyl]-1H-pyrazolo[3,4-b]pyrazin-3-yl]-3-(3-pyridyl)urea trifluoroacetate
    参考文献:
    名称:
    [EN] N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
    [FR] N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHÉNYL]-SULFONAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
    摘要:
    本发明涉及公式(I)中的N-[4-(1H-吡唑并[3,4-b]吡嗪-6-基)-苯基]-磺酰胺,其中Ar,R1,R2和n在权利要求书中所示的含义。公式(I)中的化合物是有价值的药理活性化合物,可以调节蛋白激酶活性,特别是血清和糖皮质激素调节激酶(SGK)的活性,特别是血清和糖皮质激素调节激酶亚型1(SGK-1,SGK1)的活性,并且适用于治疗SGK活性不当的疾病,例如退行性关节疾病或炎症过程,如骨关节炎或风湿病。本发明还涉及制备公式(I)中化合物的方法,它们作为药物的用途以及包含它们的制剂。
    公开号:
    WO2013041502A1
  • 作为产物:
    描述:
    盐酸sodium hydrogensulfite 、 copper(II) sulfate 作用下, 以 为溶剂, 反应 0.5h, 以52%的产率得到2-氰基-5-甲基苯磺酰氯
    参考文献:
    名称:
    AMIDINOHYDRAZONES AS PROTEASE INHIBITORS
    摘要:
    公开号:
    EP0906091B1
点击查看最新优质反应信息

文献信息

  • Metal-Free Synthesis of Pharmaceutically Important Biaryls by Photosplicing
    作者:Florian Kloss、Toni Neuwirth、Veit G. Haensch、Christian Hertweck
    DOI:10.1002/anie.201805961
    日期:2018.10.26
    neuroprotective and cholesterol‐lowering agents as well as antiarthritic non‐steroidal antiinflammatory drugs (NSAIDs). The new method was successfully employed in a total synthesis of cannabinol, an important analgesic and antiemetic therapeutic. We also report a metal‐free synthesis of key building blocks used for the preparation of sartans, antihypertensive agents that rank among the top blockbuster
    许多药物具有联芳基序,这对于它们与靶标的结合至关重要。然而,选择性交叉偶联的基准方法依赖于剧毒的重金属催化剂,这在药物合成中是不利的。另一方面,无金属的偶联反应可能需要苛刻的条件并且缺乏选择性。我们报道了一种新颖的,无金属的交叉偶联反应,该反应涉及通过一个临时的,无痕量的磺酰胺连接剂将两个苯基束缚在一起,该连接剂将光化学芳基融合引导到一个偶联产品中。可以通过环状中间体合理化反应的最佳区域和化学选择性,该中间体分解为联芳基和挥发性副产物。使用流动反应器,我们以高收率合成了许多用于重要治疗的取代联芳基结构单元,例如抗生素,抗肿瘤药,神经保护药和降胆固醇药以及抗关节炎非甾体类抗炎药(NSAIDs)。该新方法已成功用于大麻酚的全合成,大麻酚是一种重要的止痛和止吐药。我们还报告了用于制备sartan(抗高血压药)的关键构造物的无金属合成方法,该药物是全球顶级的重磅炸弹药物之一。对于广泛使用的依赖金属
  • [EN] METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES<br/>[FR] PROCÉDÉ DE PRÉPARATION SANS MÉTAL D'UN BIARYLE PAR RÉACTION DE PHOTOCOLLAGE ET UTILISATIONS ASSOCIÉES
    申请人:LEIBNIZ INST FUER NATURSTOFF FORSCHUNG UND INFEKTIONSBIOLOGIE E V HANS KNOELL INST HKI
    公开号:WO2019101679A1
    公开(公告)日:2019-05-31
    The present invention relates to a method for the metal-free preparation of a biaryl compound by a photosplicing reaction and its use in the preparation of chemical compounds, preferably of active ingredients e.g. in the fields of pharmaceuticals and agrochemicals. In particular, it refers to a method for the regiocontrolled preparation of a biaryl compound of formula (I): Ar-Ar' by photochemically reacting a precursor compound of formula (II): Ar-L-Ar' to form a biaryl compound of general formula: Ar-L-Ar' (II) → Ar-Ar' (I) wherein Ar and Ar', independently of each other, represent an unsubstituted or substituted C6-C20 aryl group or a heteroaryl group with 5–20 ring atoms selected from carbon, nitrogen, oxygen and sulfur, and L represents a group –X–Y–Z– as defined herein. The biaryl compounds are generally suitable as intermediates or key building blocks in a very broad spectrum of organic chemical syntheses and their respective utilities. Their use within the field of synthesis of active ingredients is an aspect of the invention, and their use in the preparation of pharmaceutically active ingredients is particularly preferred.
    本发明涉及一种通过光切割反应无金属制备联芳烃化合物的方法,以及其在化学化合物制备中的用途,特别是在制药和农药领域中的活性成分的制备中的用途。具体而言,它涉及一种通过光化学反应化学前体化合物(II):Ar-L-Ar'与形成一般式的联芳烃化合物(II)→Ar-Ar'(I)反应,从而实现联芳烃化合物(I)的区域控制制备的方法,其中Ar和Ar'分别表示未取代或取代的C6-C20芳基或由碳、氮、氧和硫选择的5-20个环原子的杂芳基,L表示如本文所定义的一个组-X-Y-Z-。这些联芳烃化合物通常适用于有机化学合成的广泛领域中的中间体或关键构建块,以及它们各自的用途。它们在活性成分合成领域中的用途是本发明的一个方面,它们在制备药用活性成分中的用途尤为理想。
  • [EN] CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS AYANT UNE AFFINITÉ POUR LE RÉCEPTEUR 5-HT6
    申请人:MEMORY PHARM CORP
    公开号:WO2010021797A1
    公开(公告)日:2010-02-25
    The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本公开提供了具有亲和力的化合物,其对5-HT6受体具有亲和力,其化学式为(I),其中R1、A、B、D、E、G、Q、Ar、n、m和p如本文所定义。该公开还涉及制备这种化合物的方法、含有这种化合物的组合物以及使用方法。
  • [EN] 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMPOSÉS 4'-AMINO CYCLIQUES PRÉSENTANT UNE AFFINITÉ POUR LE RÉCEPTEUR 5-HT6
    申请人:MEMORY PHARM CORP
    公开号:WO2010024980A1
    公开(公告)日:2010-03-04
    The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本公开提供了具有对5-HT6受体亲和力的化合物,其化学式为(I):化学式(I),其中Cy从化学式(II)中选择,R1、R2、R3、Q、G、Ar、m、n和p的定义如本文所述。该公开还涉及制备这种化合物的方法、含有这种化合物的组合物以及它们的使用方法。
  • Discovery of <i>N</i>-[4-(1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors
    作者:Nis Halland、Friedemann Schmidt、Tilo Weiss、Joachim Saas、Ziyu Li、Jörg Czech、Matthias Dreyer、Armin Hofmeister、Katharina Mertsch、Uwe Dietz、Carsten Strübing、Marc Nazare
    DOI:10.1021/ml5003376
    日期:2015.1.8
    From a virtual screening starting point, inhibitors of the serum and glucocorticoid regulated kinase 1 were developed through a combination of classical medicinal chemistry and library approaches. This resulted in highly active small molecules with nanomolar activity and a good overall in vitro and ADME profile. Furthermore, the compounds exhibited unusually high kinase and off-target selectivity due
    从虚拟筛选的起点出发,通过结合经典药物化学和文库方法开发了血清和糖皮质激素调节激酶1抑制剂。这产生了具有纳摩尔活性并具有良好的整体体外和ADME谱的高活性小分子。此外,由于其刚性结构,这些化合物显示出异常高的激酶和脱靶选择性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐